TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18222126

Group type: EXPERIMENTAL
Intervention: Total psychological symptom score
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Diarrhea severity
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Abdominal pain for >12 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Abdominal distension
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Frequency of bowel movements
Number of subjects: 420
Study: 16452343

Group type: EXPERIMENTAL
Intervention: ProQuad
Number of subjects: 399

Group type: COMPARATOR
Intervention: M-M-RII
Number of subjects: 399

Group type: COMPARATOR
Intervention: M-M-RII and Varivax
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: ProQuad and Varivax
Number of subjects: 399
Study: 15459598

Group type: EXPERIMENTAL
Intervention: DCA followed by stenting
Number of subjects: 86

Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 86
Study: 11527475

Group type: EXPERIMENTAL
Intervention: Resistance/endurance plus basic enhanced programming
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tai chi plus basic enhanced programming
Number of subjects: 110

Group type: COMPARATOR
Intervention: Basic enhanced programming only (Control)
Number of subjects: 110
Study: 9240291

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study: 8279351

Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 2423652

Group type: EXPERIMENTAL
Intervention: CVPP (CCNU, vinblastine, procarbazine, and prednisone)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: ABOS (bleomycin, vincristine, doxorubicin, and streptozotocin)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CVPP/ABOS (alternating cycles of CVPP and ABOS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: CVPP, ABOS, CVPP/ABOS (all treatments)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Complete responders (all treatments)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Age under 40 years (prognostic factor)
Number of subjects: 113
Study: 31732283

Group type: EXPERIMENTAL
Intervention: TACMI
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-TACMI
Number of subjects: 35
Study: 30423137

Group type: EXPERIMENTAL
Intervention: Group-supervised neuromuscular training program (UPEx-NTP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: One-on-one usual physiotherapy care (UPC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both interventions (UPEx-NTP and UPC)
Number of subjects: 31
Study: 27650174

Group type: EXPERIMENTAL
Intervention: Pelvic physiotherapy (PPT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Strengths and difficulties questionnaire (SDQ)
Number of subjects: 53
Study: 25503550

Group type: EXPERIMENTAL
Intervention: BRAIN score derived from INTERACT2 (C-statistic, 0.73) based on factors such as baseline ICH volume, recurrent ICH, anticoagulation with warfarin, intraventricular extension, and time to baseline CT.
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: BRAIN score used in INTERACT1 validation cohort.
Number of subjects: 1310
Study: 23775875

Group type: EXPERIMENTAL
Intervention: MMF/SRL
Number of subjects: 293

Group type: COMPARATOR
Intervention: MMF/CNI
Number of subjects: 293
Study: 20400651

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg (first dose 200 mg) twice daily for 5 days
Number of subjects: 11
Study: 19210652

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during unsupported arm exercise (UAE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during ground walking
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercise without NIV
Number of subjects: 32
Study: 17482983

Group type: EXPERIMENTAL
Intervention: Outreach programme promoting screening for tuberculosis
Number of subjects: 44986

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 44986
Study: 15260882

Group type: EXPERIMENTAL
Intervention: 100 mcg/day vitamin D
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 15 mcg/day vitamin D
Number of subjects: 130

Group type: COMPARATOR
Intervention: Both doses of vitamin D
Number of subjects: 130
Study: 11429371

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cuff Volume (10 mL or 30 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LMA vs PLMA at 30 mL cuff volume
Number of subjects: 0
Study: 9153526

Group type: EXPERIMENTAL
Intervention: Sensory leg discomfort condition
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined periodic limb movement and sensory leg discomfort conditions
Number of subjects: 19

Group type: COMPARATOR
Intervention: Voluntary imitation of periodic limb movements
Number of subjects: 19
Study: 8249871

Group type: EXPERIMENTAL
Intervention: Gradually increasing amounts of lactose in milk until maximum lactose dose tolerated was determined.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Breath-hydrogen tests with the maximum dose of lactose tolerated.
Number of subjects: 25
Study: 3436031

Group type: EXPERIMENTAL
Intervention: Oral mixed grass‐maize pollen extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study: 31215406

Group type: EXPERIMENTAL
Intervention: Training sessions and educational software intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study: 28650526

Group type: EXPERIMENTAL
Intervention: Formulation A (30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formulation B (30 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (30 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 18
Study: 26077087

Group type: EXPERIMENTAL
Intervention: Electrical pharyngeal stimulation (EPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 23820362

Group type: EXPERIMENTAL
Intervention: Heat Trial for 'At Risk' group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 3-mile run time for 'Not at Risk' group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Body weight comparison
Number of subjects: 56
Study: 21525251

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2296
Study: 19624856

Group type: EXPERIMENTAL
Intervention: NOP‐47 (5 g/day for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17163252

Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 80 microg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12659472

Group type: EXPERIMENTAL
Intervention: Bimanual grip selection task with wooden dowels
Number of subjects: 26
Study: 10887385

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Imipramine 150 mg/day
Number of subjects: 55
Study: 8620265

Group type: EXPERIMENTAL
Intervention: Group A (physicians given socioeconomic status or profession)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Group B (physicians given scenarios without socioeconomic status or profession)
Number of subjects: 336
Study: 1380588

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine (20 mg b.i.d.) and doxazosin (2 mg o.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 3904643

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered intravenously at 10 ng/kg/min for 72 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo administered intravenously for 72 hours
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30949987

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg twice a day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 91
Study: 29528914

Group type: EXPERIMENTAL
Intervention: Cell culture-derived subunit trivalent inactivated influenza vaccine (NBP607)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Egg-based control vaccine
Number of subjects: 374
Study: 27893095

Group type: EXPERIMENTAL
Intervention: Functional Reading Independence (FRI) Index
Number of subjects: 100
Study: 25831600

Group type: EXPERIMENTAL
Intervention: Crest Pro Health (CPH) - 700 ppm CPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate Total Puerto Rico (CT450) - 450 ppm CPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colgate Total US (CT750) - 750 ppm CPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scope Mouthwash (SCP) - 450 ppm CPC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water control (CTR)
Number of subjects: 0
Study: 22259810

Group type: EXPERIMENTAL
Intervention: Thermoelastic archwires (HANT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Superelastic archwires (SE)
Number of subjects: 30
Study: 20926040

Group type: EXPERIMENTAL
Intervention: Conventional phototherapy (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LED phototherapy (Group II)
Number of subjects: 60
Study: 18070803

Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS) exercise on a cycle ergometer until exhaustion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maximal lactate steady state (MLSS) exercise
Number of subjects: 11
Study: 16019236

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 30 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11920396

Group type: EXPERIMENTAL
Intervention: Anakinra 1.0 mg/kg + MTX
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Anakinra 2.0 mg/kg + MTX
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Anakinra (0.04, 0.1, 0.4 mg/kg) + MTX
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Anakinra + MTX
Number of subjects: 419
Study: 10796060

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a dry powder inhaler (DPI) at 22 degrees C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a dry powder inhaler (DPI) at -10 degrees C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at 22 degrees C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered from a pressurized metered dose inhaler (pMDI) at -10 degrees C after 2000 microg
Number of subjects: 14
Study: 8697553

Group type: EXPERIMENTAL
Intervention: Neostigmine (2.5‐50 micrograms.kg‐1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neostigmine (dose-dependent)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Atropine (1.2 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (ASA 1 or 2 patients with normally innervated hearts)
Number of subjects: 41
Study: 1624649

Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatic enzymes given before meals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enteric coated pancreatic enzymes given during meals
Number of subjects: 8
Study: 6734078

Group type: EXPERIMENTAL
Intervention: Non-sulphated bile acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biliary bilirubin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [3H]chenodeoxycholate-3-sulphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [14C]glycocholate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioactive sulphated bile acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biliary excretion of radioactive labelled sulphated bile acids
Number of subjects: 0
Study: 31298357

Group type: EXPERIMENTAL
Intervention: Professional oral hygiene session
Number of subjects: 10

Group type: COMPARATOR
Intervention: GCF samples from not pregnant fertile women (control group)
Number of subjects: 10
Study: 29496516

Group type: EXPERIMENTAL
Intervention: DHEA+estrogen/progestin therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25872641

Group type: EXPERIMENTAL
Intervention: Participant-customised nutrition education programme (8 weekly sessions of 2-2.5 hours)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Participant-customised nutrition education programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: Education materials only (control group)
Number of subjects: 82
Study: 24615171

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl fixed-dose combination (FDC) capsules (0.5 mg/0.2 mg)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl FDC containing 15% by weight enteric-coated tamsulosin pellets
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin HCl FDC containing 15% by weight enteric-coated tamsulosin pellets combined with uncoated tamsulosin pellets (coated:uncoated = 10:90)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Commercial Avodart™ (dutasteride 0.5 mg) and Harnal-D™ Tablets (tamsulosin 0.2 mg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Commercial Harnal™ Capsules (tamsulosin 0.2 mg)
Number of subjects: 153
Study: 22366046

Group type: EXPERIMENTAL
Intervention: External cooling to achieve normothermia (36.5‐37°C) for 48 hours
Number of subjects: 200

Group type: COMPARATOR
Intervention: No external cooling
Number of subjects: 200
Study: 20718773

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0·02, 0·04, 0·08 and 0·16 mg protein/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17504357

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (7 mg for three consecutive nights)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15258718

Group type: EXPERIMENTAL
Intervention: venlafaxine ER fixed low dose (75 mg/day)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: venlafaxine ER flexible higher dose (150-225 mg/day)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: venlafaxine ER (at any dose)
Number of subjects: 386

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 386
Study: 10910491

Group type: EXPERIMENTAL
Intervention: 15 mg meperidine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25 mg meperidine
Number of subjects: 34

Group type: COMPARATOR
Intervention: bupivicaine‐fentanyl
Number of subjects: 34
Study: 9261669

Group type: EXPERIMENTAL
Intervention: High-dose pyridoxine and magnesium (HDPM) at an average dose of 638.9 mg of pyridoxine and 216.3 mg of magnesium oxide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8275623

Group type: EXPERIMENTAL
Intervention: Oral physostigmine salicylate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3325468

Group type: EXPERIMENTAL
Intervention: IFN‐beta‐containing cream
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo cream base
Number of subjects: 15
Study: 2810009

Group type: EXPERIMENTAL
Intervention: TC film (tetracycline immobilized on a collagen film)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo film (tetracycline non-immobilized)
Number of subjects: 5
Study: 31641071

Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 40

Group type: COMPARATOR
Intervention: NIV‐PSV
Number of subjects: 40
Study: 31029880

Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF)
Number of subjects: 4460

Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF) for motivated students (score ≥3)
Number of subjects: 4460

Group type: EXPERIMENTAL
Intervention: Web-based personalized normative feedback (PNF) for low-motivated students
Number of subjects: 4460

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4460
Study: 29121291

Group type: EXPERIMENTAL
Intervention: Modified pectoral nerve block2 (mPEC2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Pectoral nerve block1 (PEC1)
Number of subjects: 62
Study: 25468685

Group type: EXPERIMENTAL
Intervention: Focal ankle joint cooling (crushed ice)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment (candy corn)
Number of subjects: 30
Study: 23172934

Group type: EXPERIMENTAL
Intervention: Indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 284
Study: 22071710

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1812
Study: 19843338

Group type: COMPARATOR
Intervention: Low-fat PS-enriched soy beverage (2 g/serving)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Moderate-fat PS-enriched soy beverage (3.5 g/serving)
Number of subjects: 56
Study: 16239059

Group type: EXPERIMENTAL
Intervention: Gingicain Spray
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Gingicaine Topical Anesthetic
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 16279276

Group type: EXPERIMENTAL
Intervention: Certification of clinical personnel for roles in the COMS
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Certification workload at the coordinating center
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Decertifications of clinical personnel
Number of subjects: 929
Study: 11208677

Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa antagonists
Number of subjects: 33326
Study: 9300508

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 37
Study: 8215000

Group type: EXPERIMENTAL
Intervention: PEEP (10 cm of H2O) in patients without a patent foramen ovale (n = 39)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PEEP (10 cm of H2O) in patients with a patent foramen ovale (n = 7)
Number of subjects: 46
Study: 3944837

Group type: EXPERIMENTAL
Intervention: Early massive excision and grafting (within 72 hours of injury) with autograft overlaid with cadaveric allograft or cadaveric allograft alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conservative treatment with daily hydrotherapy and twice daily applications of topical antimicrobial agents until granulating beds could receive autografts
Number of subjects: 13
Study: 30053934

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Aluminum Chloride
Number of subjects: 95
Study: 27131611

Group type: EXPERIMENTAL
Intervention: Anemic patients
Number of subjects: 8413
Study: 24990034

Group type: EXPERIMENTAL
Intervention: Obstacle-based Four Square Step Test (FSST)
Number of subjects: 31
Study: 22364823

Group type: EXPERIMENTAL
Intervention: Labetalol 0.4 mg/kg IV (prevention)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nicardipine 20 μg/kg IV (prevention)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Labetalol 0.4 mg/kg IV (treatment)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nicardipine 20 μg/kg IV (treatment)
Number of subjects: 130
Study: 20843249

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (initial doses based on weight)
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (higher doses)
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (poor responders)
Number of subjects: 1872
Study: 18376119

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (at least 3 times a week for 8 weeks)
Number of subjects: 37
Study: 15890990

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 12525526

Group type: EXPERIMENTAL
Intervention: Chemotherapy arm (cisplatin and fluorouracil followed by surgery)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control arm (surgery alone)
Number of subjects: 195
Study: 10967380

Group type: EXPERIMENTAL
Intervention: Aggressive treatment combining polypectomy, intra‐maxillary intubation through the inferior meatus, macrolide administration
Number of subjects: 81
Study: 9054757

Group type: EXPERIMENTAL
Intervention: ACD ACLS
Number of subjects: 512

Group type: COMPARATOR
Intervention: STD ACLS
Number of subjects: 512
Study: 8317002

Group type: EXPERIMENTAL
Intervention: Electronic rectal temperature measurement with Ivac thermometer
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Electronic rectal temperature measurement with Ivac thermometer after calibration
Number of subjects: 157

Group type: COMPARATOR
Intervention: Mercury thermometers
Number of subjects: 157
Study: 3545909

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (96 mg in three divided doses for 7 days followed by a 2-day tapering)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (same regimen as methylprednisolone)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 43
Study: 31653518

Group type: EXPERIMENTAL
Intervention: Low-phosphorus diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normal phosphorus diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-altitude exposure
Number of subjects: 8
Study: 28993396

Group type: EXPERIMENTAL
Intervention: Glucose feedback followed by biobehavioural feedback (glucose plus PA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PA feedback followed by biobehavioural feedback
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biobehavioural feedback
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45